BRAF突变型黑色素瘤治疗进展  

Progress on the treatment of BRAF-mutated melanoma

作　　者：刘欣[1,2] 张晓伟 罗志国 Xin Liu;Xiaowei Zhang;Zhiguo Luo(Department of Head&Neck Tumors and Neuroendocrine Tumors,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Gastrointestin-al Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院头颈及神经内分泌肿瘤内科,上海市200032 [2]复旦大学上海医学院肿瘤学系 [3]复旦大学附属肿瘤医院消化肿瘤内科

出　　处：《中国肿瘤临床》2022年第10期487-491,共5页Chinese Journal of Clinical Oncology

摘　　要：BRAF基因在黑色素瘤的发生发展中起重要作用,中国黑色素瘤患者中BRAF突变率为25.9%,最常见的突变位点是BRAF V600E,BRAF突变型黑色素瘤预后更差。随着新型靶向及免疫治疗药物,包括BRAF抑制剂、MEK抑制剂、程序性死亡受体-1(programmed death receptor-1,PD-1)/程序性死亡受体-1配体(programmed death receptor-1 ligand,PD-L1)抑制剂、细胞毒性T淋巴细胞相关蛋白-4(cytotoxic T-lymphocyte antigen-4,CTLA-4)抑制剂等的出现,近年来BRAF V600突变型黑色素瘤在辅助治疗及系统治疗中取得了很大的突破,本文旨在对BRAF突变型黑色素瘤的治疗进展进行综述。BRAF gene mutations play an important role in the occurrence and development of melanoma.The BRAF mutation rate in Chinese melanoma patients is 25.9%and the most common mutation is V600E.Melanoma patients with BRAF mutations have a poorer prognosis than those with wild-type BRAF.In recent years,with the discovery of new targeted agents and immunotherapeutic drugs,including BRAF inhibitors,MEK inhibitors,programmed death receptor-1(PD-1)/programmed death receptor-ligand 1(PD-L1)inhibitors,and cytotoxic T-lymphocyte antigen-4(CTLA-4)inhibitors,major progress has been made in the development of adjuvant and systemic treatments for BRAF V600-mutated melanoma.This paper reviews the research progress on the treatment of BRAF-mutated melanoma.

关 键 词：黑色素瘤 BRAF 突变 靶向治疗 免疫治疗 

分 类 号：R739.5[医药卫生—肿瘤]